ArticleNature communications2026
Soluble bacterial lipopeptides suppress gasdermin D-associated IL-33 release in keratinocytes and atopic dermatitis in mice.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The rising prevalence of allergic diseases over the last century has been linked to smaller families and the shift of populations from countryside to cities, leading to reduced exposure to environmental bacteria. We previously demonstrated that Staphylococcus aureus-derived Second immunoglobulin-binding protein (Sbi) drives type 2 immune responses and atopic dermatitis (AD). Here we show that contrary to current dogma, soluble lipopeptides, particularly diacylated lipopeptides released by Gram-positive bacteria in their stationary phase suppress type 2 immune responses in vitro and eczema in the NC/Tnd mouse model. The immunomodulatory activity of these lipopeptides is destroyed by lipoprotein lipase. Their mechanism of immunomodulation is independent of CD14 and toll-like receptor (TLR) signaling but rather associated with inhibition of caspase/gasdermin D (GSDMD)-mediated release of the interleukin (IL)-33 alarmin from the nucleus. Our findings help to explain why exposure to environmental bacteria and topical application of bacterial commensals suppresses AD. We suggest that soluble bacterial lipopeptides could be developed into a novel class of therapeutics for treatment of allergic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.